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Introduction: Nerve growth factor (NGF) level is increased in osteoarthritis (OA) joints and is involved in pain
associated with OA. Stimuli responsible for NGF stimulation in chondrocytes are unknown. We investigated whether
mechanical stress and proinflammatory cytokines may influence NGF synthesis by chondrocytes.
Methods: Primary cultures of human OA chondrocytes, newborn mouse articular chondrocytes or cartilage explants
were stimulated by increasing amounts of IL-1β, prostaglandin E2 (PGE2), visfatin/nicotinamide phosphoribosyltransferase
(NAMPT) or by cyclic mechanical compression (0.5 Hz, 1 MPa). Before stimulation, chondrocytes were pretreated with
indomethacin, Apo866, a specific inhibitor of NAMPT enzymatic activity, or transfected by siRNA targeting visfatin/
NAMPT. mRNA NGF levels were assessed by real-time quantitative PCR and NGF released into media was determined
by ELISA.
Results: Unstimulated human and mouse articular chondrocytes expressed low levels of NGF (19.2 ± 8.7 pg/mL,
13.5 ± 1.0 pg/mL and 4.4 ± 0.8 pg/mL/mg tissue for human and mouse articular chondrocytes and costal explants,
respectively). Mechanical stress induced NGF release in conditioned media. When stimulated by IL-1β or visfatin/
NAMPT, a proinflammatory adipokine produced by chondocytes in response to IL-1β, a dose-dependent increase in
NGF mRNA expression and NGF release in both human and mouse chondrocyte conditioned media was observed.
Visfatin/NAMPT is also an intracellular enzyme acting as the rate-limiting enzyme of the generation of NAD. The
expression of NGF induced by visfatin/NAMPT was inhibited by Apo866, whereas IL-1β-mediated NGF expression was
not modified by siRNA targeting visfatin/NAMPT. Interestingly, PGE2, which is produced by chondrocytes in response to
IL-1β and visfatin/NAMPT, did not stimulate NGF production. Consistently, indomethacin, a cyclooxygenase inhibitor,
did not counteract IL-1β-induced NGF production.
Conclusions: These results show that mechanical stress, IL-1β and extracellular visfatin/NAMPT, all stimulated the
expression and release of NGF by chondrocytes and thus suggest that the overexpression of visfatin/NAMPT and
IL-1β in the OA joint and the increased mechanical loading of cartilage may mediate OA pain via the stimulation
of NGF expression and release by chondrocytes.* Correspondence: francis.berenbaum@sat.aphp.fr
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Osteoarthritis (OA) is a chronic and age-related joint dis-
ease leading to cartilage destruction. Whereas the me-
chanisms by which this degradation happens are more
and more understood, the reasons why an OA joint is
painful are quite mysterious. For a same degree of carti-
lage degradation, some patients have symptoms and
others have not. Recently, novel pharmacological mole-
cules, belonging to the anti-nerve growth factor (NGF)
family, have shown a dramatic effect on OA symptoms,
much more efficacious than non-steroidal anti-inflamma-
tory drugs (NSAIDs), the usual treatment for symptomatic
OA [1-4]. Unfortunately, all clinical trials were halted in
2011 due to an unexpected increase in the number of total
joint prosthesis in the active compared to the control
groups [5]. Reviewing all the cases, it has been shown that
this increase was due to an accelerated OA process in a
few patients, especially those co-treated with NSAIDs.
Nevertheless, NGF displays proinflammatory effects,
including the stimulation of cytokine and prostaglandin E2
(PGE2) synthesis, monocyte differentiation, mast cell pro-
liferation and degranulation [6]. Moreover, the injection of
NGF into the synovium of rats increased the density of
mast cells [7].
Since there is an unmet need for treating pain in OA pa-
tients, any explanations on the occurrence of such dele-
terious effects with anti-NGF drugs are welcome. It has
been proposed that pain improvement allows increased
joint activity leading to subsequent overuse [8]. More
directly, NGF improves ligament healing [9] and dece-
lerates chondrocyte differentiation in vitro [10], which is
suspected to play an important role in OA progression. In
addition, NGF can also display anti-inflammatory effects
[11,12]. Notably, NGF inhibited interleukin (IL)-1β-
induced tumor necrosis factor-α (TNF-α) production in
OA synovial fibroblasts [13].
Inflammatory factors, including IL-1β, TNF-α and adi-
pokines [14] are found in increased levels in OA joints
and are proposed to play a role in OA progression,
especially by switching chondrocytes towards a catabolic
phenotype. IL-1β downregulates the expression of car-
tilage extracellular matrix components, while it stimulates
matrix metalloproteinase (MMP), cytokine and PGE2 syn-
thesis. Similarly, adipokines, including visfatin, stimulate
the catabolic activity of chondrocytes [14,15]. NGF levels
are increased in the synovial fluid of OA patients [16].
NGF and its two receptors, the high-affinity tyrosine
kinase A receptor (trkA) and the low-affinity p75 receptor,
are expressed by joint cells including chondrocytes [17,18]
and are increased in OA cartilage [10,19]. Moreover, NGF
synthesis is highly correlated with the degree of OA
cartilage degradation in human [19].
Interestingly, NGF expression is induced in an inflam-
matory context and mediators such as IL-1β and PGE2can stimulate NGF synthesis [13,20]. For example, intra-
articular injection of IL-1β induces an increase in NGF
levels [21]. However, stimuli responsible for NGF expres-
sion and production in OA cartilage remain to be deter-
mined. In the present study, we investigated whether
mechanical stress and proinflammatory factors, two main
determinants of OA, may influence NGF synthesis by
chondrocytes. For this purpose, primary cultures of hu-
man OA chondrocytes and newborn mouse articular
chondrocytes or cartilage explants were stimulated by
increasing amounts of IL-1β, PGE2, visfatin or by cyclic
mechanical compression. NGF mRNA expression and
protein released into media were determined.
Materials and methods
Primary culture of human chondrocytes
Human cartilage samples were obtained from OA patients
undergoing total knee arthroplasty at Saint-Antoine
Hospital (Paris, France). Informed consent was obtained for
each patient before surgery. The diagnosis of OA was based
on clinical and radiographic evaluations according to the
criteria of the American College of Rheumatology [22].
Experiments using human samples were approved by the
local ethics committee (CPP Ile de France V, 2 May 2012).
Human articular chondrocytes were isolated by enzy-
matic digestion of cartilage, as previously described [15].
Cells were seeded in 12-well plates (500,000 cells/well)
and allowed to grow to confluence in Dulbecco’s modified
Eagle’s medium (DMEM) (4.5 mg/L glucose) supple-
mented with 10% fetal calf serum, 100 IU/mL penicillin,
100 μg/mL streptomycin and 4 mM L-glutamine (Sigma-
Aldrich, Saint Quentin Fallavier, France). Cells were then
starved in serum-free medium containing 0.3% bovine
serum albumin for 24 hours before stimulation.
Primary culture of mouse chondrocytes
All experiments were performed according to the protocols
approved by the French/European ethics committee. Im-
mature murine articular chondrocytes were isolated by en-
zymatic digestion of articular cartilage from six-day-old
newborn animals from one Swiss mouse litter (Janvier
Labs, Le Genest Saint Isle, France), according to a previ-
ously described procedure [23]. Cells were seeded in 12-
well plates (10,000 cells/cm2) and allowed to grow for six to
seven days in DMEM (1 mg/L glucose) supplemented with
10% fetal calf serum, 100 IU/mL penicillin, 100 μg/mL
streptomycin and 4 mM L-glutamine (Sigma-Aldrich). Cells
were then starved in serum-free medium containing 0.1%
bovine serum albumin for 24 hours before stimulation.
Cell stimulation
Human OA and murine articular chondrocytes were
stimulated with IL-1β (PeproTech, from Tebu Bio, Le
Perray-en-Yvelines, France; 0.1 to 10 ng/mL from 2 to
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Montigny-le-Bretonneux, France; 0.1 to 10 μM for 24
hours), or visfatin (Alexis Biochemical, Paris, France; 1
to 10 μg/mL for 24 hours) dissolved in starvation media.
In additional experiments, chondrocytes were co-incu-
bated with either IL-1β (1 ng/mL) and indomethacin
(Sigma-Aldrich; 0.1 to 10 μM), an inhibitor of the cy-
clooxygenase activity, or IL-1β (1 ng/mL) and visfatin
(5 μg/mL) or visfatin (5 μg/mL) and Apo866 (10 nM)
(generously provided by Alexander So; Astellas Pharma,
Munich, Germany), an inhibitor of the nicotinamide
phosphoribosyltransferase activity of visfatin.
After stimulation, cells were disrupted in lysis buffer
(RLT, from Qiagen, Courtaboeuf, France) and condi-
tioned media were stored at −80°C until analysis.
Transfection of small interfering RNA (siRNA)
Small interfering RNA (siRNA) directed against mouse
visfatin was designed and purchased from Ambion Cenix
(Austin, TX, USA). The sequence specific for mouse vis-
fatin was forward 5’-GGCACCACUAAUCAUCAGAtt-3’,
reverse 5’-UCUGAUGAUUAGUGGUGCCtc-3’.
Mouse chondrocytes were cultured as described above.
Confluent cells were removed with trypsin, and 6 × 105
chondrocytes were seeded in 6-cm tissue culture plates
and grown for 24 hours, to 70 to 80% confluence. Nor-
mal growth medium containing 10% fetal bovine serum
was changed prior to siRNA transfection. Transfections
were performed as described for the RNAi Starter Kit
(Qiagen). Cells were incubated for 18 hours with siRNA
and transfection reagent, rinsed twice with phosphate-
buffered saline (PBS), and placed in DMEM (1 mg/L
glucose) supplemented with penicillin, streptomycin, and
L-glutamine containing 1% BSA, with or without IL-1β
(10 ng/ml) for 24 hours. Transfection of siRNA against
MAPK-1, a ubiquitously produced mouse cell protein,
was used as a positive control. A nonsilencing siRNA
that has no homology with any known mammalian gene
(RNAi Starter Kit) and scrambled siRNA (Ambion) were
used as negative controls.
Mechanical compression
Mechanical compression was applied on costal cartilage, as
previously described [24]. Briefly, ribs cages from six-day-
old newborns from one Swiss mouse litter (Janvier Labs)
were harvested and cartilage was separated from bone and
soft tissues. Immediately after dissection, each sample, con-
sisting of 50 mg of cartilage explants, were placed into Bio-
press culture plates (Flexercell International, Hillsborough,
NC, USA) in DMEM (1 mg/L glucose) supplemented with
30 mM Hepes, 100 IU/mL penicillin, 100 μg/mL strep-
tomycin and 4 mM L-glutamine (Sigma-Aldrich). During 4
to 24 hours, intermittent compression was applied by
the Biopress system (Flexercell International) using asinusoidal waveform at 0.5 Hz and 1.0 MPa of magnitude
(Figure S1 in Additional file 1). Control explants were kept
in unloaded condition.
After compression, cartilage explants frizzed in liquid
nitrogen and conditioned media were stored at −80°C
until analysis.
RNA extraction, reverse transcription and quantitative
real-time PCR
Total RNA was extracted from cultured cells with RNeasy
Mini kit (Qiagen) according to the manufacturer’s instruc-
tions. Total RNA was reverse transcribed with Omniscript
RT kit according to the manufacturer's instructions
(Qiagen). NGF mRNA expression was analyzed by quanti-
tative real-time PCR using the Light Cycler 480 (Roche
Diagnostics, Meylan, France). The equivalent of 5 to 10 ng
initial RNA was subjected to PCR amplification in a 12 μl
final volume using specific primers at 10 μM and LC 480
SYBR Green I Master kit (Roche Diagnostics). PCR ampli-
fication conditions were: initial denaturation for 5 min at
95°C followed by 40 cycles consisting of 10 s at 95°C, 15 s
at 60°C and 10 s at 72°C. Product formation was detected
at 72°C in the fluorescein isothiocyanate channel. The
generation of specific PCR products was confirmed by
melting curve analysis. For each PCR, cDNAs were run in
duplicate in parallel with serial dilutions of a cDNA mix-
ture tested for each primer pair to generate a standard lin-
ear curve, which was used to estimate the amplification
efficiency for NGF and HPRT. The relative mRNA expres-
sion of NGF normalized to that of HPRT, used as internal
reference gene, was determined by the Efficiency method
of the LightCycler 480 Software.
The specific oligonucleotide primers used were as fol-
lows: human NGF, sense 5’GTCATCATCCCATCCCAT
CT3’ and anti-sense 5’AGTACTGTTTGAATACACTGT
TGTTAAT3’; mouse NGF, sense 5’CACCCACCCAGTC
TTCC3’ and anti-sense 5’CTCGGCACTTGGTCTCAAA3’;
human GAPDH, sense 5’CCATCACCATCTTCCA3’ and
anti-sense 5’CCTTCTCCATGGTGGT3’; mouse HPRT,
sense, 5’GCTGGTGAAAAGGACCTCT3’ and anti-sense,
5’CACAGGACTAGAACACCTGC3’.
NGF assay
NGF concentrations in the medium were measured using
an enzyme-linked immunosorbent assay (ELISA) kit from
Promega (Charbonnières, France) according to the manu-
facturer’s instructions. The detection limit of NGF was
7.8 pg/mL and the intra-assay coefficients of variance was
4.2%. The NGF concentrations were analyzed in duplicate
at serial dilution and were read against a standard curve.
Statistical analysis
Results are expressed as means ± standard deviation
(SD). Results were compared using one-way factorial
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F test (Statview software, version 4.57; Abacus Concepts
Inc., Berkeley, CA, USA). Statistical significance was
accepted for P <0.05.
Results
Induction of NGF expression and release by costal
cartilage explants in response to mechanical stress
Since mechanical overload is considered as a strong
inducer of cartilage damage and pain, the influence of
in vitro mechanical compression on NGF release by cos-
tal cartilage explants was investigated. For this purpose,
murine costal cartilages were subjected to intermittent
compression for 4 and 24 hours. Costal cartilage ex-
plants constitutively released low levels of NGF that
accumulated within conditioned media between 4 and
24 hours (Figure 1A). Compression for 4 hours did not
stimulate NGF release. In contrast, accumulation of
NGF into tissue-conditioned media was significantly in-
creased after compression for 24 hours (4.7-fold increase
versus control, P = 0.04) (Figure 1).
Induction of NGF expression and release by articular
chondrocytes in response to visfatin
Visfatin is an adipokine found in OA synovial fluids [25],
which displays catabolic activity on chondrocytes [15]. We
thus determined whether NGF expression and release
could be modulated by visfatin. Human OA and mouse
articular chondrocytes were stimulated with increasing
concentrations of visfatin (1, 2.5, 5 and 10 μg/mL) for
24 hours and NGF mRNA expression and release into
conditioned media was measured. Both human and mouse
























Figure 1 Stimulation of NGF release by cartilage compression.
Explants of costal cartilages from Swiss mice were compressed (C) or
not (NC) for 4 and 24 hours (n = 4). NGF protein levels were
measured in conditioned media. *P <0.05. NGF, nerve growth factor.mRNA and protein (Figure 2). Visfatin induced a dose-
dependent increase in NGF mRNA expression in human
OA chondrocytes (Figure 2A). The stimulation of NGF
mRNA expression was observed with 1 μg/mL visfatin
and became statistically significant with 2.5 μg/mL visfatin
(14-fold increase as compared to control, P = 0.02).
Consequently, an accumulation of NGF into human chon-
drocyte-conditioned media was measured after visfatin
stimulation (Figure 2B). Similarly, a dose-dependent
increased accumulation of NGF was observed in condi-
tioned media of mouse articular chondrocytes (Figure 2C).
A significant increase, as compared to unstimulated chon-
drocytes, was obtained with 2.5 μg/mL visfatin (2.6-fold
versus control, P = 0.03) and the highest concentration of
visfatin (10 μg/mL) induced the highest accumulation
of NGF into cell supernatant (4.9-fold versus control,
P = 0.0003) (Figure 2C). Visfatin-mediated release of NGF
was associated with an increase in NGF mRNA expression
(2-fold versus control, P = 0.045) (Figure 2C, inset).
In addition to its cytokine-like activity, visfatin displays a
nicotinamide phosphoribosyltransferase (NAMPT) enzy-
matic activity responsible for the synthesis of nicotinamide
adenine dinucleotide (NAD). Several lines of evidence
support the involvement of this enzymatic activity in the
cellular effects of visfatin/NAMPT [26]. To investigate
the involvement of visfatin/NAMPT enzymatic activity
in NGF stimulation, chondrocytes were pretreated with
10 nM Apo866, a specific inhibitor of NAMPT [27], for
4 hours before the addition of exogenous visfatin/NAMPT
(5 μg/mL). Apo866 treatment led to a 56% and 68% drop
in NAD concentration in control and visfatin/NAMPT-
treated chondrocytes (P = 0.0003 and P <0.0001, respec-
tively) (not shown). The inhibition of visfatin/NAMPT
enzymatic activity by Apo866 prevented the increase in
NGF synthesis (P = 0.02 versus visfatin/NAMPT-treated
cells without Apo866) (Figure 2D). In contrast, no modifi-
cation of spontaneous release of NGF by chondrocytes
was observed in the presence of Apo866.
Induction of NGF expression and release by articular
chondrocytes in response to IL-1β
We next investigated the action of IL-1β on NGF mRNA
expression and release by human OA and murine arti-
cular chondrocytes. IL-1β dose-dependently increased
NGF mRNA expression in human OA articular chon-
drocytes (Figure 3A). A 9.3-fold induction was observed
with 0.1 ng/mL IL-1β and became statistically significant
with 1 ng/mL (P = 0.004). This was associated with in-
creased levels of NGF measured in conditioned media of
chondrocytes stimulated with IL-1β (Figure 3B). IL-1β
also stimulated NGF mRNA expression in mouse articu-
lar chondrocytes since a 1.8-fold induction was observed
with 0.1 ng/mL IL-1β and became statistically significant



























































































































Figure 2 Visfatin induces NGF expression and release by chondrocytes. Human OA chondrocytes were stimulated for 24 hours with
increasing concentrations of visfatin (0, 1, 2.5 and 5 μg/mL) and NGF mRNA expression (A) and release into cell supernatant (B) were measured
by quantitative RT-PCR and ELISA, respectively (n = 3) Control cells released 20.4 ± 12.2 pg/mL NGF. (C) Primary cultures of mouse articular
chondrocytes were stimulated for 24 hours with increasing concentration of visfatin (0, 1, 2.5, 5 and 10 μg/mL) and NGF levels were measured
in conditioned media (n = 3). Inset: NGF mRNA expression was determined by quantitative RT-PCR in control cells and chondrocytes stimulated with
visfatin (5 μg/mL) for 24 hours. The amount of NGF mRNA was normalized against the amount of HPRT mRNA measured in the same cDNA. (D) Mouse
articular chondrocytes were incubated with or without Apo866 (10 nM) for 4 hours and then treated or not with visfatin (5 μg/mL) for 24 hours (n = 3).
NGF release was determined into cell-conditioned media. *P <0.05, **P <0.01, ***P <0.001. ELISA, enzyme-linked immunosorbent assay; NGF, nerve
growth factor; OA, osteoarthritis.
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to control, P = 0.004). IL-1β-induced NGF mRNA ex-
pression paralleled the release of NGF protein into cell-
conditioned media (Figure 3C and D). NGF protein re-
lease was slightly increased at 0.1 ng/mL and this in-
crease became significant at 1 ng/mL IL-1β (P = 0.024).
In the time-course experiment, IL-1β-induced NGF re-
lease was observed after a 4-hour stimulation (4.2-fold
increase versus control, P = 0.049) and further increased
up to 24 hours (9.2-fold increase versus control, P =
0.0005) (Figure 3E).
IL-1β is a strong inducer of PGE2 synthesis by cartilage
and chondrocytes. However, PGE2 was not involved in
IL-1β-mediated NGF stimulation. Indeed, PGE2 (0.01 to
10 μM) did not stimulate NGF release by articular chon-
drocytes (Figure 4A). Furthermore, indomethacin (0.1 to10 μM), a specific inhibitor of cyclooxygenase enzymatic
activity, was unable to prevent the release of NGF induced
by IL-1β (1 ng/mL) (Figure 4B), although it efficiently
inhibited the IL-1β-mediated production of PGE2 by
chondrocytes (not shown).
Since some of the effects of IL-1β on chondrocytes in-
volve visfatin/NAMPT [15], consequences of visfatin/
NAMPT knockdown on IL-1β-mediated NGF stimula-
tion were assessed (Figure 4C). No effect of visfatin/
NAMPT siRNA on the constitutive release of NGF was
observed. Similarly, the potent stimulation of NGF se-
cretion induced by IL-1β (10 ng/mL) (5-fold as com-
pared to control, P >0.0002) was not blocked by visfatin/
NAMPT siRNA, suggesting that endogenous visfatin/
NAMPT is not involved in the IL-1β-stimulated release
of NGF by chondrocytes (Figure 4C).
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Figure 3 Stimulation of articular chondrocyte expression and release of NGF by IL-1β. Human OA chondrocytes were stimulated for 24 hours
with increasing concentrations of IL-1β (0, 0.1, 1 and 10 ng/mL) and NGF mRNA expression (A) and release into cell supernatant (B) were measured by
quantitative RT-PCR and ELISA, respectively (n = 4). Control cells released 19.2 ± 8.7 pg/mL NGF. (C-E) Primary cultures of mouse articular chondrocytes
were stimulated either with increasing concentrations of IL-1β (0, 0.1, 1 and 10 ng/mL) for 24 hours (n = 3) (C and D) or with IL-1β (10 ng/mL) for 2, 4, 6,
8 and 24 hours (n = 3) (E). As a control (ctrl), chondrocytes were incubated without IL-1β for 24 hours (E). NGF mRNA expression was determined by
quantitative RT-PCR (C). The amount of NGF mRNA was normalized against the amount of HPRT mRNA measured in the same cDNA. NGF protein levels
were measured in conditioned media by ELISA (D and E). *P <0.05, **P <0.01, ***P <0.001. ELISA, enzyme-linked immunosorbent assay; IL-1β, interleukin
1β; NGF, nerve growth factor; OA, osteoarthritis.
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release by visfatin/NAMPT
To determine whether the stimulation of NGF mRNA
expression and release by IL-1β and visfatin/NAMPT
could be additive, murine articular chondrocytes were co-
stimulated with IL-1β (1 ng/mL) and visfatin/NAMPT
(5 μg/mL). A slight potentiation of IL-1β-mediated sti-
mulation of NGF was observed both at mRNA (1.4-fold)
and protein levels (1.3-fold) when chondrocytes were
co-stimulated with visfatin/NAMPT (Figure 5). This
potentiation was similar to the stimulatory effect of
visfatin/NAPMT since visfatin/NAMPT induced a 1.5-fold
and 1.4-fold stimulation of NGF mRNA expression and
release, respectively (Figure 5). Compression did not fur-
ther increase the release of NGF from cartilage induced by
either IL-1β or visfatin/NAMPT or IL-1β and visfatin/
NAMPT (not shown).Discussion
Several lines of evidence highlight NGF as an attractive
therapeutic target to control OA pain. NGF is a key factor
in inflammation-associated hyperalgesia, whose protein is
detected in OA synovial fluid [16] and mRNA expression
is enhanced in OA chondrocytes [19]. NGF may also me-
diate joint damage [6]. Preclinical studies on experimental
models of joint pain [1,3] and clinical trials on OA patients
[2,4] thus evidenced the efficiency of NGF targeting in the
reduction of joint pain. However, the increased number of
total joint prosthesis due to acceleration in lesion progres-
sion in some patients decided the FDA to stop all clinical
trials. A better understanding of the involvement of NGF
in OA is therefore required. In this study, we investigated
whether proinflammatory factors and mechanical com-
pression, the main determinants of OA, may lead to the
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Figure 4 PGE2 and endogenous visaftin/NAMPT are not involved in IL-1β-mediated stimulation of NGF release by articular chondrocytes.
(A and B) Primary cultures of mouse articular chondrocytes were stimulated for 24 hours either with increasing concentrations of PGE2 (0, 0.01, 0.01,
1 and 10 ng/mL) (n = 3) (A) or with IL-1β (1 ng/mL) in the presence of increasing concentrations of indomethacin (0, 0.1, 1, 10 μM) (n = 3) (B). As a
control (ctrl), chondrocytes were incubated without IL-1β for 24 hours (B). NGF protein levels were measured in conditioned media by ELISA. (C) Primary
culture of mouse articular chondrocytes were transfected by siRNA targeting visfatin/NAMPT before stimulation with IL-1β (10 ng/mL) for 24 hours
(n = 2). Each experiment was performed in triplicate. Results are expressed as NGF release as compared to IL-1β-stimulated chondrocytes. *P <0.05,
***P <0.001. ELISA, enzyme-linked immunosorbent assay; IL-1β, interleukin 1β; NAMPT, nicotinamide phosphoribosyltransferase activity. Supress activity;


























































Figure 5 Potentiation of IL-1β-stimulated NGF expression and release by visfatin/NAMPT. Primary cultures of mouse articular chondrocytes
were stimulated or not for 24 hours either with IL-1β (1 ng/mL) or visfatin/NAMPT (5 μg/mL) or with IL-1β (1 ng/mL) and visfatin/NAMPT (5 μg/mL)
(n = 3). The mRNA expression of NGF (A) and the NGF protein levels in chondrocyte conditioned media were determined (B). *P <0.05, ***P <0.001.
IL-1β, interleukin 1β; NAMPT, nicotinamide phosphoribosyltransferase activity. Supress activity; NGF, nerve growth factor.
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mouse cartilage and articular chondrocytes constitutively
expressed NGF mRNA and released NGF protein into
conditioned media, as already reported by Iannone et al.
[19] in human normal articular chondrocytes. We also
observed an increase in NGF expression and release in
response to OA stimuli, consistently with the enhanced
expression of NGF by OA chondrocytes [19]. In this
context, we show for the first time that dynamic com-
pression induced the release of NGF by cartilage,
highlighting NGF as a mechanosensitive gene in chon-
drocytes. This result is in accordance with data showing
that mechanical stretch can modulate NGF expression
with an induction observed in smooth muscle cells [28]
and sympathetic neurocytes [29], whereas a downregula-
tion was obtained in rat cardiomyocytes [30].
We also show that IL-1β, which is considered as the
main inflammatory mediator involved in cartilage
degradation in OA, induced in a time- and dose-
dependent manner an increase in NGF expression and
release by both human and mouse articular chondro-
cytes. Similarly, IL-1β has been reported to stimulate
the expression of NGF in several cell types, including
human nucleus pulposus cells isolated from patients
with intervertebral disc (IVD) degeneration [31-33].
The intra-articular injection of IL-1β induced an in-
crease in NGF levels [21] and a positive correlation bet-
ween IL-1β and NGF immunostaining in human IVD
tissues was observed [34].
In addition to its well-known pro-degradative property
on cartilage, IL-1β plays also a role in joint pain. Indeed,
IL-1β levels in OA synovial fluids are associated with
pain and hyperalgesia of the temporomandibular joint
[35] and the synovial mRNA expression of IL-1β is cor-
related with the degree of pain in rotator cuff diseases
[36]. OA patients showing a 2-fold higher expression of
IL-1β by peripheral blood leukocytes compared to non-
OA controls have higher pain scores and risks of radio-
graphic OA progression than patients displaying similar
peripheral blood leukocyte IL-1β expression than non-
OA controls [37]. Furthermore, a reduced pain was
obtained following the treatment of patients with
chronic active gouty arthritis with rilonacept, an inhi-
bitor of IL-1β [38]. Similarly, the subcutaneous injection
of canakinumab, an anti-human IL-1β antibody, to pa-
tients with cryopyrin-associated periodic syndrome pro-
voked a sustained remission of symptoms, including
pain [39]. All these data suggest that IL-1β-mediated
stimulation of NGF expression by chondrocytes may
account for the pain associated with IL-1β levels in OA
joints.
Adipokines have recently been proposed as molecular
mediators probably involved in OA [40]. Among them,
visfatin/NAMPT was characterized as a visceral fatcytokine, a 52 kDa protein with insulin mimetic activity
[41]. Visfatin/NAMPT is released by all joint tissues in
OA patients [25] and its concentration in synovial fluids is
linked to cartilage degradation biomarkers [42]. Visfatin/
NAMPT stimulates chondrocyte catabolic activity mea-
sured by PGE2 and protease synthesis [15] and induces
the expression of several proinflammatory cytokines by
chondrocytes (Laiguillon, submitted). Our results show
that visfatin also stimulated both NGF expression and
release by human OA and mouse articular chondro-
cytes, suggesting that it may favor OA pain in addition
to mediate cartilage damage.
In addition to its cytokine-like activity, visfatin dis-
plays a NAMPT enzymatic activity responsible for the
synthesis of NAD. NAD biosynthetic activity of visfatin/
NAMPT is involved in some cellular effects of ex-
tracellular visfatin/NAMPT [43-45]. Interestingly, the
pharmacological inhibition of visfatin/NAMPT by
Apo866, a specific inhibitor of NAMPT activity, pre-
vents arthritis progression [46,47]. In a previous study,
we showed that blocking NAMPT enzymatic activity
inhibited the catabolic response of chondrocytes to ex-
ogenous visfatin/NAMPT [26]. Similarly, we show here
that NAMPT enzymatic activity was also crucial for
the visfatin/NAMPT-mediated NGF stimulation in
chondrocytes, suggesting the involvement of NAD in
the signaling pathway of visfatin/NAMPT leading to
NGF expression. NAD-consuming proteins, including
sirtuins and poly(ADP-ribose) polymerases (PARPs),
are known actors in the expression of many genes [48].
However, nothing is known about a putative role
of such proteins in the expression of NGF. In addi-
tion, NAD consumption generates second messengers,
which contribute to intracellular calcium signaling
[49]. Intracellular calcium can regulate the expression
of NGF [28,30].
IL-1β-mediated NGF expression involves nuclear fac-
tor kappa B (NF-κB) activity [50]. Interestingly, the pro-
inflammatory effect of visfatin/NAMPT requires NF-κB
activity in a NAMPT enzymatic activity-dependent
manner. Some of the effects of IL-1β involve endo-
genous visfatin/NAMPT, as demonstrated by siRNA
strategy [15]. However, we did not obtain any inhibition
of IL-1β-mediated NGF secretion by using siRNA tar-
geting endogenous visfatin/NAMPT, showing that
endogenous visfatin/NAMPT is not involved in the
stimulation of NGF induced by IL-1β. As NAD-derived
second messengers activate intracellular calcium sig-
naling, these results could explain why intracellular cal-
cium signaling is not involved in IL-1β-mediated NGF
expression [51]. Taken together, our results support that
different signaling pathways, requiring endogenous
visfatin/NAMPT or not, can be activated by IL-1β. Our
results also show that the stimulation of NGF
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NAMPT involves different pathways, thus explaining
the potentiation of IL-1β-mediated stimulation of NGF
expression and release by visfatin/NAMPT.
Interestingly, mechanical loading, IL-1β and visfatin
all induce PGE2 production by cartilage and chondro-
cytes [15,52,53]. PGE2 was reported to induce the ex-
pression of NGF in mouse astrocyte cultures [54,55].
Blocking the generation of prostaglandins by celecoxib
(Celebrex) prevented the increased secretion of NGF by
tooth perfusates in rats after an inflammatory stress
[56]. PGE2 may be also involved in IL-1β-mediated pain
[57]. PGE2 may thus represent a common way for NGF
expression in chondrocytes in response to OA stimuli.
However, our results show that PGE2, whatever the con-
centration used, was unable to induce NGF expression
and release in chondrocytes. In addition, indomethacin,
an inhibitor of cyclooxygenase enzymatic activity, did
not prevent the IL-1β-mediated increase in NGF ex-
pression in chondrocytes. These results suggest that the
increased chondrocyte expression of NGF in response
to several OA stimuli did not involve PGE2. In contrast,
other studies showed that PGE2 modulates the expres-
sion and synthesis of NGF. Friedman et al. reported that
indomethacin partly blocked the increase in NGF pro-
duction in response to IL-1β in embryonic rat hippo-
campal cultures [20]. PGE2 stimulates the secretion of
NGF in astrocytes [54,55], whereas in 3T3-L1 adipo-
cytes it decreases both NGF expression and synthesis
[58]. Thus, the influence of PGE2 on NGF synthesis ap-
pears to be cell-type-dependent and may be related to
the differential expression pattern of PGE2 receptor in
these cells. High amounts of E-type prostanoid (EP)3 re-
ceptor are indeed expressed in mature adipocytes [59],
whereas chondrocytes express low levels of EP3 [60,61].
Conclusions
OA is a painful disease, in which NGF plays a crucial role.
Indeed, pivotal clinical trials have demonstrated that
counteracting NGF leads to a dramatic reduction of OA
pain [2]. Unfortunately, all the NGF antibodies in develop-
ment have induced an acceleration of the OA process in a
subgroup of patients. It is thus mandatory to accumulate
more information on the mechanism of action of NGF in
order to enhance the benefit-risk ratio of this new family
of effective symptomatic drugs. Our results show that two
main OA determinants, mechanical stress and proinflam-
matory factors, including IL-1β and extracellular visfatin/
NAMPT, stimulated the expression and the release of
NGF by articular chondrocytes. These results suggest that
OA pain may involve the release of NGF by chondrocytes
in response to the increased levels of IL-1β and extracellu-
lar visfatin/NAMPT, and to the increased mechanical
loading of cartilage.Additional file
Additional file 1: Figure S1. Compression system. (A) FX-4000C™
Flexercell™ Compression Plus™ System (Flexcell International Corp., Hillsborough,
NC, USA). A positive pressure compresses samples between a piston and
stationary platen on the BioPress™ culture. (B) Schematic diagram of the
BioPress™ culture plate compression chamber in uncompressed or
compressed position.
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